Not surprisingly, there is much interest in testing established anti-hypertensive therapies for their potential insulin-sensitizing functions which may improve the metabolic parameters as additional benefits, providing a dual protection against the key features of metabolic syndrome [7–9]. The gene discussed is INS; the disease is metabolic syndrome.